These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 34435337)

  • 41. Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis.
    Tai YL; Lee MD; Chi H; Chiu NC; Lei WT; Weng SL; Liu LY; Chen CC; Huang SY; Huang YN; Lin CY
    PeerJ; 2023; 11():e15344. PubMed ID: 37180576
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19.
    Arimura K; Tagaya E; Kikuchi K; Mitsuda T; Ebihara F; Maruyama T; Hamada Y; Unagami K; Kanzawa T; Sekiguchi H; Shimamoto K; Ishida H; Egawa H; Tanaka J; Kawana M
    Transpl Immunol; 2023 Apr; 77():101777. PubMed ID: 36584927
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.
    Jovanoski N; Kuznik A; Becker U; Hussein M; Briggs A
    J Manag Care Spec Pharm; 2022 May; 28(5):555-565. PubMed ID: 35238626
    [No Abstract]   [Full Text] [Related]  

  • 44. Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria.
    Schiaroli E; De Socio GV; Gidari A; Malincarne L; Benedetti S; Lanzi A; Bastianelli S; Pierucci S; Busti C; Fagotti B; Vicenti I; Zazzi M; Francisci D
    Mediterr J Hematol Infect Dis; 2022; 14(1):e2022050. PubMed ID: 35865399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.
    Nathan R; Shawa I; De La Torre I; Pustizzi JM; Haustrup N; Patel DR; Huhn G
    Infect Dis Ther; 2021 Dec; 10(4):1933-1947. PubMed ID: 34374951
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic.
    Suzuki Y; Shibata Y; Minemura H; Nikaido T; Tanino Y; Fukuhara A; Kanno R; Saito H; Suzuki S; Ishii T; Inokoshi Y; Sando E; Sakuma H; Kobayashi T; Kume H; Kamimoto M; Aoki H; Takama A; Kamiyama T; Nakayama M; Saito K; Tanigawa K; Sato M; Kanbe T; Kanzaki N; Azuma T; Sakamoto K; Nakamura Y; Ohtani H; Waragai M; Maeda S; Ishida T; Sugino K; Tsukada Y; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Watanabe N; Rikimaru M; Kawamata T; Umeda T; Morimoto J; Togawa R; Sato Y; Saito J; Kanazawa K; Iseki K
    Int J Med Sci; 2022; 19(5):834-841. PubMed ID: 35693744
    [No Abstract]   [Full Text] [Related]  

  • 47. Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy.
    Focosi D; Tuccori M
    Pathogens; 2022 Jul; 11(8):. PubMed ID: 35894046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19.
    Med Lett Drugs Ther; 2021 Oct; 63(1635):163-164. PubMed ID: 35050242
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review.
    Ravi G; Eerike M; Konda VR; Bisoi D; Raj GM; Priyadarshini R; Mali KR; Chaliserry LF
    Monoclon Antib Immunodiagn Immunother; 2023 Apr; 42(2):77-94. PubMed ID: 37129306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant.
    Cicchitto G; Cardillo L; de Martinis C; Sabatini P; Marchitiello R; Abate G; Rovetti A; Cavallera A; Apuzzo C; Ferrigno F; Fusco G
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.
    Belote A; Reece S; Robinson S; Jensen H; CarlLee S; Clark M; Parnell S; Geels C; Newton J
    Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):210-213. PubMed ID: 35920868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic monoclonal antibodies for COVID-19 management: an update.
    Chavda VP; Prajapati R; Lathigara D; Nagar B; Kukadiya J; Redwan EM; Uversky VN; Kher MN; Patel R
    Expert Opin Biol Ther; 2022 Jun; 22(6):763-780. PubMed ID: 35604379
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of a subcutaneous casirivimab and imdevimab clinic in outpatients with symptomatic COVID-19: A single-center, propensity-matched cohort study.
    Rhudy C; Bochenek S; Thomas J; St James G; Zeltner M; Platt T
    Am J Health Syst Pharm; 2023 Jan; 80(3):130-136. PubMed ID: 36264659
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An EUA for bamlanivimab and etesevimab for COVID-19.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):49-50. PubMed ID: 33830966
    [No Abstract]   [Full Text] [Related]  

  • 55. The effect of casirivimab with imdevimab on disease progression in nonsevere COVID-19 patients in a single hospital in Japan.
    Komagamine J; Yabuki T; Yoshihara S; Tanaka N
    J Gen Fam Med; 2022 May; 23(3):158-163. PubMed ID: 35509339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. COVID-19: A Review of Potential Treatments (Corticosteroids, Remdesivir, Tocilizumab, Bamlanivimab/Etesevimab, and Casirivimab/Imdevimab) and Pharmacological Considerations.
    Nhean S; Varela ME; Nguyen YN; Juarez A; Huynh T; Udeh D; Tseng AL
    J Pharm Pract; 2023 Apr; 36(2):407-417. PubMed ID: 34597525
    [No Abstract]   [Full Text] [Related]  

  • 57. PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together.
    Ernest CS; Chien JY; Patel DR; Chigutsa E
    CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):721-730. PubMed ID: 35289125
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.
    Wolf J; Abzug MJ; Anosike BI; Vora SB; Waghmare A; Sue PK; Olivero RM; Oliveira CR; James SH; Morton TH; Maron GM; Young JL; Orscheln RC; Schwenk HT; Bio LL; Willis ZI; Lloyd EC; Hersh AL; Huskins CW; Soma VL; Ratner AJ; Hayes M; Downes K; Chiotos K; Grapentine SP; Wattier RL; Lamb GS; Zachariah P; Nakamura MM
    J Pediatric Infect Dis Soc; 2022 May; 11(5):177-185. PubMed ID: 35107571
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial.
    Chen P; Behre G; Hebert C; Kumar P; Farmer Macpherson L; Graham-Clarke PL; De La Torre I; Nichols RM; Hufford MM; Patel DR; Naegeli AN
    Open Forum Infect Dis; 2022 May; 9(5):ofac172. PubMed ID: 35493124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbidities.
    Monday LM; Brar I; Alangaden G; Ramesh MS
    J Clin Pharm Ther; 2022 Sep; 47(9):1438-1443. PubMed ID: 35633095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.